## Fiscal quarter ended

 December 2017- supplementary financial summary -

February 7, 2018
Asahi Kasei Corporation

## Contents

## Consolidated results for fiscal quarter ended Dec. 2017

| Summary of financial results | 4 | Consolidated operating <br> performance forecast | 16 |
| :--- | ---: | :--- | ---: |
| Statements of income | 5 | Forecast by business category | $17-18$ |
| Extraordinary income and loss | 6 | Forecast by segment <br> Appendix | 19 |
| Balance sheets | 7 | Performance by business <br> category | $21-22$ |
| Cash flows | $9-10$ | Overseas sales by business <br> category <br> Statements of comprehensive <br> income <br> Overview of results by business <br> category | $25-34$ |
| Sales and operating income by <br> segment <br> Sales and operating income by <br> business category | $11-14$ |  | 24 |

## Forecast for fiscal year 2017

Consolidated operating ..... 6Forecast by business category9
Performance by business2324Overview of results by business 25-34category

# Consolidated results for fiscal quarter ended Dec. 2017 

Period from April 1 to December 31, 2017, and October 1 to December 31, 2017.

## Summary of financial results

|  | 2016 |  | 2017 |  |
| :--- | ---: | ---: | ---: | ---: |
|  | Oct.-Dec. | Apr.-Dec. | Oct.-Dec. | Apr.-Dec. <br> $a$ |
| Net sales | 466.1 | $1,356.8$ | 519.8 | $1,484.5$ |
| Operating income | 43.4 | 114.1 | 56.5 | 149.2 |
| Ordinary income | 48.5 | 118.4 | 62.4 | 160.5 |
| Net income attributable <br> to owners of the parent | 36.7 | 89.7 | 69.5 | 140.3 |


| Oct.-Dec. <br> 2017 vs. 2016 |  | Apr.-Dec. <br> 2017 vs. 2016 |  |
| ---: | ---: | ---: | ---: |
| Increase <br> (decrease) | \% change | Increase <br> (decrease) | \% change |
| 53.7 | $+11.5 \%$ | 127.7 | $+9.4 \%$ |
| 13.2 | $+30.4 \%$ | 35.1 | $+30.7 \%$ |
| 13.8 | $+28.5 \%$ | 42.2 | $+35.6 \%$ |
| 32.7 | $+89.1 \%$ | 50.7 | $+56.5 \%$ |


| FY 2017 <br> forecast <br> in Nov. <br> $b$ | $\%$ of <br> forecast <br> $a / b$ |
| :---: | :---: |
| $2,000.0$ | $74.2 \%$ |
| 183.0 | $81.5 \%$ |
| 192.0 | $83.6 \%$ |
| 140.0 | $100.2 \%$ |

Key operating factors

| Naphtha price <br> $(¥ / \mathrm{kL}$, domestic) | 34,000 | 32,300 | 44,600 | 39,933 |
| :--- | ---: | ---: | ---: | ---: |
| $¥ / \mathrm{US} \$$ exchange rate <br> (market average) | 109 | 107 | 113 | 112 |
| $¥ / €$ exchange rate <br> (market average) | 118 | 118 | 133 | 129 |

Financial position

|  | At end of <br> Mar. 2017 | At end of <br> Dec. 2017 |
| :--- | ---: | ---: |
| Total assets | $2,254.5$ | $2,422.5$ |
| Equity | $1,151.3$ | $1,300.6$ |
| Interest-bearing debt | 402.8 | 402.3 |
| Debt/equity ratio | 0.35 | 0.31 |


|  | 2016 |  |  |  | 2017 |  |  |  | $\begin{gathered} \text { Oct.-Dec. } \\ 2017 \text { vs. } 2016 \end{gathered}$ |  | $\begin{gathered} \text { Apr.-Dec. } \\ 2017 \text { vs. } 2016 \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Oct.-Dec. |  | Apr.-Dec. |  | Oct.-Dec. |  | Apr.-Dec. |  | Increase | \% chan | Increase <br> (decrease) | \% change |
| Net sales | 466.1 | 100.0\% | 1,356.8 | 100.0\% | 519.8 | 100.0\% | 1,484.5 | 100.0\% | 53.7 | +11.5\% | 127.7 | +9.4\% |
| Cost of sales | 317.8 | 68.2\% | 928.7 | 68.4\% | 351.0 | 67.5\% | 1,002.5 | 67.5\% | 33.2 | +10.4\% | 73.8 | +8.0\% |
| Gross profit | 148.4 | 31.8\% | 428.2 | 31.6\% | 168.8 | 32.5\% | 482.0 | 32.5\% | 20.5 | +13.8\% | 53.9 | +12.6\% |
| Selling, general and administrative expenses | 105.0 | 22.5\% | 314.0 | 23.1\% | 112.3 | 21.6\% | 332.8 | 22.4\% | 7.3 | +7.0\% | 18.8 | +6.0\% |
| Operating income | 43.4 | 9.3\% | 114.1 | 8.4\% | 56.5 | 10.9\% | 149.2 | 10.0\% | 13.2 | +30.4\% | 35.1 | +30.7\% |
| Net non-operating income (expenses) of which, net financing income (expenses) net equity in earnings (losses) of affiliates foreign exchange gains (loss) | 5.2 <br> 0.6 <br> 1.3 <br> 3.6 |  | $\begin{aligned} & 4.3 \\ & 1.7 \\ & 2.6 \\ & 0.3 \end{aligned}$ |  | 5.8 <br> 2.2 <br> 3.8 <br> (0.6) |  | 11.4 <br> 3.6 <br> 9.1 <br> (1.5) |  | 0.7 <br> 1.5 <br> 2.5 <br> (4.2) |  | 7.1 <br> 1.9 <br> 6.5 <br> (1.8) |  |
| Ordinary income | 48.5 | 10.4\% | 118.4 | 8.7\% | 62.4 | 12.0\% | 160.5 | 10.8\% | 13.8 | +28.5\% | 42.2 | +35.6\% |
| Net extraordinary income (loss) | 2.2 |  | 3.0 |  | 7.3 |  | 10.8 |  | 5.1 |  | 7.8 | , |
| Income before income taxes | 50.7 | 10.9\% | 121.4 | 8.9\% | 69.7 | 13.4\% | 171.4 | 11.5\% | 19.0 | +37.4\% | 50.0 | +41.1\% |
| Total Income taxes <br> Net income attributable to non-controlling interests | $(13.5)$ (0.5) |  | $\begin{gathered} (30.4) \\ (1.3) \end{gathered}$ |  | $\begin{gathered} 0.3 \\ (0.5) \end{gathered}$ |  | $\begin{gathered} (29.5) \\ (1.6) \end{gathered}$ |  | $\begin{array}{r} 13.7 \\ 0.0 \end{array}$ |  | $\begin{gathered} 1.0 \\ (0.2) \end{gathered}$ |  |
| Net income attributable to owners of the parent | 36.7 | 7.9\% | 89.7 | 6.6\% | 69.5 | 13.4\% | 140.3 | 9.5\% | 32.7 | +89.1\% | 50.7 | +56.5\% |

## Extraordinary income and loss

|  | 2016 |  | 2017 |  | Oct.-Dec. | Apr.-Dec. |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Oct.-Dec. | Apr.-Dec. | Oct.-Dec. | Apr.-Dec. | '17 vs. '16 <br> Increase <br> (decrease) | '17 vs. '16 <br> Increase <br> (decrease) |
| Gain on sales of investment securities | 6.0 | 9.9 | 9.2 | 15.1 | 3.3 | 5.2 |
| Gain on sales of noncurrent assets | 0.0 | 0.1 | 0.1 | 0.5 | 0.1 | 0.5 |
| Total extraordinary income | 6.0 | 9.9 | 9.4 | 15.6 | 3.3 | 5.7 |
| Loss on valuation of investment securities | 0.0 | 0.0 | 0.0 | 0.0 | (0.0) | (0.0) |
| Loss on disposal of noncurrent assets | 1.0 | 2.3 | 1.4 | 2.9 | 0.4 | 0.6 |
| Impairment loss | 0.0 | 0.1 | 0.3 | 0.9 | 0.3 | 0.8 |
| Business structure improvement expenses | 2.8 | 3.8 | 0.4 | 1.1 | (2.4) | (2.8) |
| Business integration expense | 0.0 | 0.7 | - | - | (0.0) | (0.7) |
| Total extraordinary loss | 3.8 | 6.9 | 2.0 | 4.8 | (1.8) | (2.1) |
| Net extraordinary income (loss) | 2.2 | 3.0 | 7.3 | 10.8 | 5.1 | 7.8 |

## Balance sheets

AsahiKASEI


## Cash flows

|  | 2016 |  | 2017 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Oct.-Dec. | Apr.-Dec. | Oct.-Dec. | Apr.-Dec. |
| a. Net cash provided by (used in) operating activities | 33.2 | 123.7 | 39.0 | 154.0 |
| b. Net cash provided by (used in) investing activities | (12.6) | (63.1) | (16.1) | (69.1) |
| c. Free cash flows [a+b] | 20.7 | 60.6 | 22.9 | 85.0 |
| d. Net cash provided by (used in) financing activities | 29.9 | (13.4) | 2.8 | (43.1) |
| Effect of exchange rate change on cash and cash <br> e. equivalents | 4.9 | (5.1) | 4.0 | 5.1 |
| f. Net increase (decrease) in cash and cash equivalents [ $\mathrm{c}+\mathrm{d}+\mathrm{e}$ ] | 55.4 | 42.0 | 29.7 | 47.0 |


| g. Cash and cash equivalents at beginning of period | 132.3 | 145.3 | 161.6 | 144.1 |
| :--- | ---: | ---: | ---: | ---: |
| h. Increase in cash and cash equivalents resulting from <br> changes in scope of consolidation | - | 0.4 | - | 0.3 |
| i. Cash and cash equivalents at end of period [f+g+h] | 187.8 | 187.8 | 191.3 | 191.3 |

## Sales and operating income by segment, Oct.-Dec. 2016 and 2017

## AsahiKASEI

( $¥$ billion)

|  | Sales |  |  | Operating income |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Oct.-Dec. <br> 2016 | Oct.-Dec. <br> 2017 | Increase <br> (decrease) | Oct.-Dec. <br> 2016 | Oct.-Dec. <br> 2017 | Increase <br> (decrease) |
|  | 253.0 | 288.6 | 35.6 | 27.4 | 36.8 | 9.4 |
| Homes | 139.5 | 149.3 | 9.7 | 12.4 | 13.3 | 0.9 |
| Health Care | 69.1 | 77.5 | 8.5 | 9.4 | 13.5 | 4.2 |
| Others $^{1}$ | 4.5 | 4.4 | $(0.1)$ | 0.4 | 0.4 | 0.0 |
| Corporate expenses and <br> eliminations | - | - | - | $(6.3)$ | $(7.5)$ | $(1.2)$ |
| Consolidated | 466.1 | 519.8 | 53.7 | 43.4 | 56.5 | 13.2 |

${ }^{1}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification.

Sales and operating income by segment, Apr.-Dec. 2016 and 2017
( $¥$ billion)

|  | Sales |  |  | Operating income |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Apr.-Dec. <br> 2016 | Apr.-Dec. <br> 2017 | Increase <br> (decrease) | Apr.-Dec. <br> 2016 | Apr.-Dec. <br> 2017 | Increase <br> (decrease) |
|  | 717.0 | 807.5 | 90.6 | 66.4 | 97.5 | 31.2 |
| Homes | 427.0 | 445.0 | 18.0 | 38.9 | 39.4 | 0.5 |
| Health Care $^{\text {Cthers }}{ }^{1}$ | 201.4 | 220.0 | 18.7 | 26.9 | 32.0 | 5.0 |
| Corporate expenses and $_{\text {eliminations }}$ | 11.5 | 12.0 | 0.5 | 1.3 | 1.1 | $(0.2)$ |
| Consolidated | - | - | - | $(19.3)$ | $(20.8)$ | $(1.5)$ |

[^0]Sales and operating income increase/decrease by business category ${ }^{1}$, Oct.-Dec. 2017 vs. 2016 (i)
( $¥$ billion)

|  |  | $\begin{array}{\|c} \text { Oct.-Dec. } \\ 2016 \end{array}$ | $\begin{gathered} \text { Oct.-Dec. } \\ 2017 \end{gathered}$ | Net increase (decrease) | Increase (decrease) due to: |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales volume |  |  | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| Fibers | Sales |  | 31.4 | 34.7 | 3.3 | 1.9 | 0.6 | 0.2 | 0.9 | - |
|  | Operating income | 3.4 | 3.0 | (0.3) | 0.6 | - |  |  | (1.5) |
| Chemicals ${ }^{2}$ | Sales | 185.2 | 214.1 | 28.9 | 9.8 | 15.7 | 2.7 | 3.4 | - |
|  | Operating income | 22.4 | 30.1 | 7.8 | 4.0 |  |  | - | (12.0) |
| Electronics | Sales | 36.4 | 39.8 | 3.5 | 3.1 | (0.3) | 0.5 | 0.7 | - |
|  | Operating income | 1.7 | 3.7 | 2.0 | 1.1 |  |  | - | 1.1 |
| Homes | Sales | 125.4 | 134.7 | 9.3 | 1.2 | 0.0 | - | 8.1 | - |
|  | Operating income | 10.8 | 11.9 | 1.1 | 1.3 |  |  | - | (0.2) |
| Construction <br> Materials | Sales | 14.1 | 14.5 | 0.4 | 0.4 | 0.0 | - | - | - |
|  | Operating income | 1.9 | 1.7 | (0.2) | 0.2 |  |  | - | (0.4) |

[^1]Sales and operating income increase/decrease by business category ${ }^{1}$, Oct.-Dec. 2017 vs. 2016 (ii)
( $¥$ billion)

|  |  | $\begin{gathered} \text { Oct.-Dec. } \\ 2016 \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { Oct.-Dec. } \\ 2017 \end{array}$ | Net increase (decrease) | Increase (decrease) due to: |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales volume |  |  | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| Health Care | Sales |  | 34.3 | 36.7 | 2.4 | 0.4 | 0.5 | 0.0 | 1.6 | - |
|  | Operating income | 5.4 | 8.2 | 2.8 | 0.5 | - |  |  | 1.8 |
| Critical Care | Sales | 34.8 | 40.8 | 6.0 | 4.3 | 0.4 | 0.3 | 1.3 | - |
|  | Operating income | 4.0 | 5.4 | 1.4 | 2.5 |  |  | - | (1.5) |
| Others ${ }^{2}$ | Sales | 4.5 | 4.4 | (0.1) | (0.1) | - | - | - | - |
|  | Operating income | 0.4 | 0.4 | 0.0 | (0.3) |  |  | - | 0.4 |
| Corporate expenses and eliminations | $\begin{aligned} & \text { Operating } \\ & \text { loss } \\ & \hline \end{aligned}$ | (6.5) | (7.9) | (1.3) | - | - | - | - | (1.3) |
| Consolidated | Sales | 466.1 | 519.8 | 53.7 | 20.9 | 16.8 | 3.8 | 15.9 | - |
|  | Operating income | 43.4 | 56.5 | 13.2 | 9.8 |  |  | - | (13.5) |

[^2]Sales and operating income increase/decrease by business category ${ }^{1}$, Apr.-Dec. 2017 vs. 2016 (i)

## AsahiKASEI

(¥ billion)

|  |  | $\begin{array}{\|c} \text { Apr.-Dec. } \\ 2016 \end{array}$ | $\begin{array}{\|c\|} \hline \text { Apr.-Dec. } \\ 2017 \end{array}$ | Net increase (decrease) | Increase (decrease) due to: |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales volume |  |  | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| Fibers | Sales |  | 93.7 | 100.8 | 7.1 | 3.9 | 1.3 | 0.6 | 1.9 | - |
|  | Operating income | 9.3 | 9.6 | 0.2 | 1.9 | - |  |  | (3.0) |
| Chemicals ${ }^{2}$ | Sales | 520.0 | 589.2 | 69.2 | 13.7 | 48.1 | 8.5 | 7.5 | - |
|  | Operating income | 55.6 | 78.7 | 23.1 | 8.5 |  |  | - | (33.5) |
| Electronics | Sales | 103.3 | 117.5 | 14.2 | 12.6 | (0.8) | 1.9 | 2.4 | - |
|  | Operating income | 1.4 | 9.3 | 7.8 | 4.1 |  |  | - | 4.5 |
| Homes | Sales | 390.3 | 404.3 | 14.1 | 5.3 | 0.5 | - | 8.3 | - |
|  | Operating income | 35.4 | 36.2 | 0.8 | 2.0 |  |  | - | (1.7) |
| Construction <br> Materials | Sales | 36.7 | 40.6 | 3.9 | 3.2 | (0.2) | - | 0.9 | - |
|  | Operating income | 3.7 | 3.5 | (0.2) | 1.4 |  |  | - | (1.3) |

[^3]Sales and operating income increase/decrease by business category ${ }^{1}$, Apr.-Dec. 2017 vs. 2016 (ii)

|  |  | $\begin{gathered} \text { Apr.-Dec. } \\ 2016 \end{gathered}$ | $\begin{gathered} \text { Apr.-Dec. } \\ 2017 \end{gathered}$ | Net increase (decrease) | Increase (decrease) due to: |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales volume |  |  | Sales prices | of which, due to foreign exchange | Others | Operating <br> costs and others |
| Health Care | Sales |  | 102.1 | 103.1 | 1.0 | (2.3) | 0.9 | 0.1 | 2.4 | - |
|  | Operating income | 16.1 | 18.1 | 1.9 | (1.2) | - |  |  | 2.2 |
| Critical Care | Sales | 99.2 | 117.0 | 17.7 | 11.6 | 0.8 | 0.4 | 5.3 | - |
|  | Operating income | 10.8 | 13.9 | 3.1 | 6.6 |  |  | - | (4.3) |
| Others ${ }^{2}$ | Sales | 11.5 | 12.0 | 0.5 | 0.5 | - | - | - | - |
|  | Operating income | 1.3 | 1.1 | (0.2) | (0.1) |  |  | - | (0.1) |
| Corporate expenses and eliminations | Operating <br> loss | (19.5) | (21.1) | (1.6) | - | - | - | - | (1.6) |
| Consolidated | Sales | 1,356.8 | 1,484.5 | 127.7 | 48.5 | 50.5 | 11.4 | 28.7 | - |
|  | Operating income | 114.1 | 149.2 | 35.1 | 23.3 |  |  | - | (38.8) |

[^4]
## AsahiKASEI

## Forecast for fiscal year 2017

Consolidated operating performance forecast

|  | FY 2016 |  |  | FY 2017 revised forecast |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | H1 | H2 | Total | H1 |  |  | H2 | Total |
|  |  |  |  |  | Oct.-Dec. | Jan.-Mar. | forecast |  |
| Net sales | 890.7 | 992.3 | 1,883.0 | 964.7 | 519.8 | 565.5 | 1,085.3 | 2,050.0 |
| Operating income | 70.8 | 88.5 | 159.2 | 92.7 | 56.5 | 45.8 | 102.3 | 195.0 |
| Ordinary income | 69.9 | 90.8 | 160.6 | 98.2 | 62.4 | 47.5 | 109.8 | 208.0 |
| Net income attributable to owners of the parent | 52.9 | 62.1 | 115.0 | 70.9 | 69.5 | 28.7 | 98.1 | 169.0 |


| $(¥$ billion) |  |
| ---: | ---: |
| FY 2017 <br> forecast <br> in Nov. | Increase <br> (decrease) |
| $2,000.0$ | 50.0 |
| 183.0 | 12.0 |
| 192.0 | 16.0 |
| 140.0 | 29.0 |

Key operating factors

| Naphtha price <br> $(¥ / \mathrm{kL}$, domestic) | 31,450 | 37,900 | 34,675 | 37,600 | 44,600 | 49,200 | 46,900 | 42,250 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| $¥ /$ US\$ exchange rate <br> (market average) | 105 | 112 | 108 | 111 | 113 | 110 | 111 | 111 |
| $¥ / €$ exchange rate <br> (market average) | 118 | 119 | 119 | 126 | 133 | 130 | 132 | 129 |


| 40,800 | 1,450 |
| ---: | ---: |
| 111 | 1 |
| 128 | 1 |


|  | FY 2016 | FY 2017 |
| :--- | :---: | :---: |
| Dividends per share | $¥ 24$ | $¥ 28$ <br> (planned) |
| Payout ratio | $29.1 \%$ | $23.1 \%$ |

## Sales forecast by business category

| ( $¥$ billion) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY 2016 |  | Total | FY 2017 revised forecast |  |  |  | Total a | FY 2017 forecast in Nov. b | Increase (decrease)$a-b$ |
|  | H1 | H2 |  | H1 | Oct.-Dec. | Jan.-Mar. | H2 <br> forecast |  |  |  |
| Fibers | 62.3 | 63.4 | 125.7 | 66.1 | 34.7 | 34.2 | 68.9 | 135.0 | 135.0 | - |
| Chemicals ${ }^{1}$ | 334.8 | 378.0 | 712.8 | 375.2 | 214.1 | 217.8 | 431.8 | 807.0 | 761.0 | 46.0 |
| Electronics | 66.9 | 72.5 | 139.4 | 77.7 | 39.8 | 36.5 | 76.3 | 154.0 | 154.0 | - |
| Homes | 264.8 | 305.3 | 570.2 | 269.6 | 134.7 | 183.7 | 318.4 | 588.0 | 588.0 | - |
| Construction Materials | 22.6 | 26.2 | 48.8 | 26.1 | 14.5 | 12.4 | 26.9 | 53.0 | 53.0 | - |
| Health Care | 67.8 | 66.1 | 133.9 | 66.3 | 36.7 | 32.9 | 69.7 | 136.0 | 136.0 | - |
| Critical Care | 64.5 | 71.7 | 136.2 | 76.2 | 40.8 | 43.0 | 83.8 | 160.0 | 156.0 | 4.0 |
| Others ${ }^{1}$ | 7.0 | 9.0 | 16.0 | 7.6 | 4.4 | 5.0 | 9.4 | 17.0 | 17.0 | - |
| Consolidated | 890.7 | 992.3 | 1,883.0 | 964.7 | 519.8 | 565.5 | 1,085.3 | 2,050.0 | 2,000.0 | 50.0 |

[^5]
## Operating income (loss) forecast by business category ${ }^{1}$

## AsahiKASEI

| ( $¥$ billion) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY 2016 |  | Total | FY 2017 revised forecast |  |  |  | Total <br> a | FY 2017 <br> forecast <br> in Nov. <br> b | Increase (decrease) $a-b$ |
|  | H1 | H2 |  | H1 | Oct.-Dec. | Jan.-Mar. | $\begin{gathered} \mathrm{H} 2 \\ \text { forecast } \end{gathered}$ |  |  |  |
| Fibers | 6.0 | 5.7 | 11.7 | 6.6 | 3.0 | 2.9 | 5.9 | 12.5 | 12.5 | - |
| Chemicals ${ }^{2}$ | 33.3 | 41.1 | 74.4 | 48.6 | 30.1 | 19.3 | 49.4 | 98.0 | 88.5 | 9.5 |
| Electronics | (0.3) | 2.8 | 2.5 | 5.6 | 3.7 | (0.3) | 3.4 | 9.0 | 7.5 | 1.5 |
| Homes | 24.6 | 34.9 | 59.5 | 24.3 | 11.9 | 23.8 | 35.7 | 60.0 | 60.0 | - |
| Construction Materials | 1.8 | 2.6 | 4.5 | 1.8 | 1.7 | 1.0 | 2.7 | 4.5 | 4.5 | - |
| Health Care | 10.7 | 6.4 | 17.1 | 9.9 | 8.2 | 0.9 | 9.1 | 19.0 | 18.0 | 1.0 |
| Critical Care | 6.8 | 8.0 | 14.8 | 8.5 | 5.4 | 5.6 | 11.0 | 19.5 | 18.5 | 1.0 |
| Others ${ }^{2}$ | 0.9 | 1.2 | 2.0 | 0.7 | 0.4 | 0.4 | 0.8 | 1.5 | 1.5 | - |
| Corporate expenses and eliminations | (13.0) | (14.1) | (27.1) | (13.3) | (7.9) | (7.9) | (15.7) | (29.0) | (28.0) | (1.0) |
| Consolidated | 70.8 | 88.5 | 159.2 | 92.7 | 56.5 | 45.8 | 102.3 | 195.0 | 183.0 | 12.0 |

[^6]
## Sales and operating income forecast by segment

## Sales forecast

( $¥$ billion)

|  | FY 2016 |  | Total | FY 2017 revised forecast |  |  |  | Total <br> a | FY 2017 <br> forecast <br> in Nov. <br> b | Increase (decrease)$a-b$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | H1 | H2 |  | H1 | Oct.-Dec. | Jan.-Mar. | H2 <br> forecast |  |  |  |
| Material ${ }^{1}$ | 464.0 | 513.9 | 977.9 | 518.9 | 288.6 | 288.5 | 577.1 | 1,096.0 | 1,050.0 | 46.0 |
| Homes | 287.5 | 331.5 | 619.0 | 295.7 | 149.3 | 196.0 | 345.3 | 641.0 | 641.0 | - |
| Health Care | 132.3 | 137.8 | 270.1 | 142.5 | 77.5 | 76.0 | 153.5 | 296.0 | 292.0 | 4.0 |
| Others ${ }^{1}$ | 7.0 | 9.0 | 16.0 | 7.6 | 4.4 | 5.0 | 9.4 | 17.0 | 17.0 | - |
| Consolidated | 890.7 | 992.3 | 1,883.0 | 964.7 | 519.8 | 565.5 | 1,085.3 | 2,050.0 | 2,000.0 | 50.0 |

## Operating income forecast

( $¥$ billion)

|  | FY 2016 |  | Total | FY 2017 revised forecast |  |  |  | Total <br> a | FY 2017 forecast in Nov. b | Increase (decrease)$a-b$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | H1 | H2 |  | H1 | Oct.-Dec. | Jan.-Mar. | $\begin{gathered} \mathrm{H} 2 \\ \text { forecast } \end{gathered}$ |  |  |  |
| Material ${ }^{1}$ | 38.9 | 49.6 | 88.5 | 60.7 | 36.8 | 22.0 | 58.8 | 119.5 | 108.5 | 11.0 |
| Homes | 26.5 | 37.6 | 64.1 | 26.1 | 13.3 | 25.1 | 38.4 | 64.5 | 64.5 | - |
| Health Care | 17.6 | 14.4 | 31.9 | 18.4 | 13.5 | 6.5 | 20.1 | 38.5 | 36.5 | 2.0 |
| Others ${ }^{1}$ | 0.9 | 1.2 | 2.0 | 0.7 | 0.4 | 0.4 | 0.8 | 1.5 | 1.5 | - |
| Corporate expenses and eliminations | (13.1) | (14.2) | (27.3) | (13.3) | (7.5) | (8.2) | (15.7) | (29.0) | (28.0) | (1.0) |
| Consolidated | 70.8 | 88.5 | 159.2 | 92.7 | 56.5 | 45.8 | 102.3 | 195.0 | 183.0 | 12.0 |

[^7]
## AsahiKASEI

## Appendix

## Quarterly sales by business category

|  | FY 2016 |  |  |  | FY 2017 |  |  | FY 2017 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 <br> forecast |
| Fibers | 30.9 | 31.4 | 31.4 | 32.0 | 32.0 | 34.1 | 34.7 | 34.2 |
| Chemicals ${ }^{1}$ | 167.0 | 167.9 | 185.2 | 192.8 | 178.3 | 196.8 | 214.1 | 217.8 |
| Electronics | 32.2 | 34.7 | 36.4 | 36.1 | 36.5 | 41.2 | 39.8 | 36.5 |
| Homes | 115.7 | 149.1 | 125.4 | 179.9 | 115.6 | 154.0 | 134.7 | 183.7 |
| Construction Materials | 10.3 | 12.3 | 14.1 | 12.1 | 12.6 | 13.5 | 14.5 | 12.4 |
| Health Care | 34.5 | 33.3 | 34.3 | 31.8 | 32.7 | 33.6 | 36.7 | 32.9 |
| Critical Care | 32.2 | 32.3 | 34.8 | 37.0 | 37.3 | 38.8 | 40.8 | 43.0 |
| Others ${ }^{1}$ | 2.9 | 4.1 | 4.5 | 4.5 | 3.6 | 4.0 | 4.4 | 5.0 |
| Total | 425.8 | 464.9 | 466.1 | 526.1 | 448.7 | 516.0 | 519.8 | 565.5 |

${ }^{1}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

Quarterly operating income (loss) by business category ${ }^{1}$

|  | FY 2016 |  |  |  | FY 2017 |  |  | FY 2017 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 <br> forecast |
| Fibers | 3.3 | 2.7 | 3.4 | 2.3 | 3.5 | 3.1 | 3.0 | 2.9 |
| Chemicals ${ }^{2}$ | 14.7 | 18.6 | 22.4 | 18.8 | 22.5 | 26.0 | 30.1 | 19.3 |
| Electronics | (0.1) | (0.2) | 1.7 | 1.0 | 2.0 | 3.6 | 3.7 | (0.3) |
| Homes | 7.8 | 16.8 | 10.8 | 24.1 | 6.9 | 17.3 | 11.9 | 23.8 |
| Construction Materials | 0.9 | 1.0 | 1.9 | 0.8 | 0.7 | 1.1 | 1.7 | 1.0 |
| Health Care | 6.8 | 4.0 | 5.4 | 1.0 | 5.3 | 4.6 | 8.2 | 0.9 |
| Critical Care | 2.8 | 4.0 | 4.0 | 4.0 | 3.7 | 4.8 | 5.4 | 5.6 |
| Others ${ }^{2}$ | 0.2 | 0.7 | 0.4 | 0.7 | 0.0 | 0.6 | 0.4 | 0.4 |
| Corporate expenses and eliminations | (6.4) | (6.6) | (6.5) | (7.6) | (6.9) | (6.4) | (7.9) | (7.9) |
| Total | 29.9 | 40.9 | 43.4 | 45.1 | 37.9 | 54.8 | 56.5 | 45.8 |

[^8]Overseas sales by business category, Apr.-Dec. 2016 and 2017
( $¥$ billion)

|  | Apr.-Dec. 2016 |  |  | Apr.-Dec. 2017 |  |  | Increase (decrease) in overseas sales |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Overseas sales |  | Total sales | Overseas |  |  |  |
|  |  |  | \% of total |  | sales | \% of total |  | \% change |
| Fibers | 93.7 | 39.0 | 41.6\% | 100.8 | 44.3 | 43.9\% | 5.3 | +13.5\% |
| Chemicals ${ }^{1}$ | 520.0 | 242.3 | 46.6\% | 589.2 | 288.6 | 49.0\% | 46.3 | +19.1\% |
| Electronics | 103.3 | 71.4 | 69.1\% | 117.5 | 81.4 | 69.3\% | 10.0 | +14.0\% |
| Homes | 390.3 | - | - | 404.3 | - | - | - | - |
| Construction Materials | 36.7 | 0.0 | 0.0\% | 40.6 | 0.0 | 0.0\% | 0.0 | - |
| Health Care | 102.1 | 29.2 | 28.6\% | 103.1 | 31.0 | 30.0\% | 1.7 | +5.9\% |
| Critical Care | 99.2 | 98.2 | 98.9\% | 117.0 | 115.5 | 98.7\% | 17.3 | +17.6\% |
| Others ${ }^{1}$ | 11.5 | 1.8 | 15.4\% | 12.0 | 2.7 | 22.1\% | 0.9 | +49.2\% |
| Total | 1,356.8 | 481.9 | 35.5\% | 1,484.5 | 563.4 | 38.0\% | 81.5 | +16.9\% |
| Sales to East Asia ${ }^{2}$ |  | 216.2 | 15.9\% |  | 255.4 | 17.2\% | 39.1 | +18.1\% |
| of which, sales to China |  | 124.3 | 9.2\% |  | 140.6 | 9.5\% | 16.2 | +13.1\% |
| Sales, excluding Homes and | 929.9 | 481.9 | 51.8\% | 1,039.6 | 563.4 | 54.2\% |  |  |

[^9]|  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
| a: Net income | 2016 <br> Apr.-Dec. | 2017 <br> Apr.-Dec. |  |  |


| $\quad$ ( $¥$ billion) |
| :---: |
| Increase |
| (decrease) |$|$


| Net increase or decrease in unrealized gain on other securities | 16.6 | 20.6 | 4.1 |
| :---: | :---: | :---: | :---: |
| Deferred gains or losses on hedges | 0.2 | (0.0) | (0.2) |
| Foreign currency translation adjustment | 8.2 | 20.9 | 12.7 |
| Remeasurements of defined benefit plans | 6.3 | 5.9 | (0.4) |
| Share of other comprehensive income of affiliates accounted for using equity method | 0.3 | 1.5 | 1.2 |
| b: Other comprehensive income | 31.6 | 48.9 | 17.3 |
| Comprehensive income [a+b] | 122.6 | 190.8 | 68.2 |
| Comprehensive income attributable to owners of the parent | 121.1 | 188.7 | 67.7 |
| Comprehensive income attributable to non-controlling interests | 1.5 | 2.1 | 0.5 |

## AsahiKASEI



## Review of operations

Impact of higher feedstock costs. Strong performance of Lamous microfiber suede. Sales increase and slight operating income increase.
Highlights

- September, decision to increase production capacity for Lamous microfiber suede in Nobeokashi, Miyazaki, Japan.
- January, decision to increase production capacity for Leona nylon 66 filament in Nobeoka-shi, Miyazaki, Japan.

[^10]
## Chemicals ${ }^{1}$

## AsahiKASEI





## Review of operations

Order-built homes:

- Decreased deliveries of Hebel Maison apartment buildings. Increased SG\&A expenses such as advertising expenses. Sales and operating income decrease.
- Value of new orders flat year-on-year. Increased value of new orders for multi-dwelling homes with firm demand for apartment buildings, but decreased value for unit homes.
Real estate, remodeling and others:
Firm performance of rental management and condominium construction in real estate. Solid performance in remodeling. Sales and operating income increase.


## Highlights

- May, new high-durability double-layer insulation system adopted in all products.
- June, start of sales of Hebel Haus Cubic Roomy, a new model of the main product series of Hebel Haus Cubic two-story unit homes.
- August, formation of capital alliance with McDonald Jones Homes Pty Ltd, an Australian company which constructs and sells unit homes.
- November, launch of promotion to commemorate 50th anniversary of production of Hebel autoclaved aerated concrete in Japan.


## Homes (ii)

Sales ${ }^{1}$ and order trends
( $¥$ billion, $\%$ indicates year-on-year comparison)

|  |  | Value of new orders during the term | Sales of orderbuilt homes, etc. ${ }^{1}$ | Sales of real estate ${ }^{1}$ |  |  | Total | Sales of remodeling | Other sales | Consolidated | Order <br> backlog |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Pre-built <br> homes |  | Rental housing | Other |  |  |  |  |  |
| FY13 | H1 |  | 251.9 (+21.4\%) | 181.0 (+12.1\%) | 4.5 | 26.2 | 1.4 | 32.1 | 24.5 | 0.8 | 238.4 (+11.9\%) | 519.9 |
|  | H2 | 169.4 (-17.3\%) | 213.1 (+3.5\%) | 24.8 | 27.9 | 1.1 | 53.7 | 28.1 | 1.1 | 296.0 (+8.4\%) | 481.5 |
|  | annual | 421.3 (+2.2\%) | 394.1 (+7.3\%) | 29.3 | 54.1 | 2.5 | 85.8 | 52.6 | 1.9 | 534.4 (+9.9\%) |  |
| FY14 | H1 | 217.6 (-13.6\%) | 187.9 (+3.9\%) | 9.8 | 29.3 | 1.4 | 40.6 | 26.3 | 1.1 | 256.0 (+7.4\%) | 516.3 |
|  | H2 | 208.0 (+22.8\%) | 216.2 (+1.5\%) | 18.0 | 31.8 | 1.6 | 51.4 | 27.3 | 0.9 | 295.8 (-0.1\%) | 514.5 |
|  | annual | 425.7 (+1.0\%) | 404.2 (+2.6\%) | 27.8 | 61.1 | 3.1 | 92.0 | 53.6 | 2.0 | 551.8 (+3.3\%) |  |
| FY15 | H1 | 217.3 (-0.2\%) | 183.8 (-2.2\%) | 10.4 | 33.5 | 1.7 | 45.6 | 27.8 | 0.9 | 258.0 (+0.8\%) | 554.6 |
|  | H2 | 183.1 (-12.0\%) | 227.7 (+5.3\%) | 27.7 | 39.0 | 1.8 | 68.4 | 28.1 | 0.7 | 325.0 (+9.9\%) | 513.1 |
|  | annual | 400.4 (-5.9\%) | 411.5 (+1.8\%) | 38.1 | 72.5 | 3.5 | 114.1 | 55.9 | 1.6 | 583.0 (+5.7\%) |  |
| FY16 | H1 | 206.6 (-4.9\%) | 183.5 (-0.1\%) | 11.8 | 41.2 | 1.8 | 54.8 | 27.0 | (0.5) | 264.8 (+2.6\%) | 538.8 |
|  | Q3 | 89.5 (+5.5\%) | 87.2 (-7.3\%) | 1.0 | 21.1 | 0.8 | 23.0 | 14.8 | 0.4 | 125.4 (-13.2\%) | 542.7 |
|  | H2 | 194.3 (+6.1\%) | 220.8 (-3.1\%) | 9.5 | 43.5 | 1.6 | 54.6 | 29.1 | 0.8 | 305.3 (-6.1\%) | 515.8 |
|  | annual | 400.9 (+0.1\%) | 404.3 (-1.8\%) | 21.3 | 84.7 | 3.4 | 109.4 | 56.1 | 0.4 | 570.2 (-2.2\%) |  |
| FY17 | H1 | 193.1 (-6.5\%) | 182.7 (-0.4\%) | 12.0 | 45.3 | 1.6 | 59.0 | 26.8 | 1.1 | 269.6 (+1.8\%) | 528.9 |
|  | Q3 | 104.1 (+16.4\%) | 86.0 (-1.4\%) | 9.2 | 23.2 | 1.3 | 33.7 | 14.4 | 0.6 | 134.7 (+7.4\%) | 548.5 |
|  | H2 <br> forecast | 215.8 (+11.0\%) | 223.3 (+1.1\%) | 15.0 | 47.7 | 2.4 | 65.0 | 28.7 | 1.4 | 318.4 (+4.3\%) | 524.6 |
|  | annual forecast | 408.8 (+2.0\%) | 406.0 (+0.4\%) | 27.0 | 93.0 | 4.0 | 124.0 | 55.5 | 2.5 | 588.0 (+3.1\%) |  |

[^11]
## Construction Materials




## Health Care (ii)

Sales of Health Care business category

|  | FY 2016 |  | Total | FY 2017 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Oct.-Dec. | Apr.-Dec. |  | Oct.-Dec. | Apr.-Dec. |
| Domestic pharamaceuticals | 16.3 | 47.5 | 61.5 | 16.5 | 47.0 |
| Others | 1.5 | 4.9 | 6.4 | 1.1 | 3.9 |
| Asahi Kasei Pharma consolidated | 17.8 | 52.4 | 67.8 | 17.6 | 50.9 |
| Devices ${ }^{1}$ | 16.6 | 49.7 | 66.1 | 19.1 | 52.2 |
| Total | 34.4 | 102.1 | 133.9 | 36.7 | 103.1 |

${ }^{1}$ Asahi Kasei Medical and its affiliate companies.

## Main pharmaceuticals domestic sales

( $¥$ billion)

|  | FY 2016 |  | Total | FY 2017 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Oct.-Dec. | Apr.-Dec. |  | Oct.-Dec. | Apr.-Dec. |
| Teribone | 6.1 | 18.1 | 23.9 | 7.2 | 20.5 |
| Recomodulin | 3.7 | 10.0 | 12.6 | 3.5 | 9.3 |
| Flivas | 1.5 | 4.7 | 5.9 | 1.3 | 3.7 |
| Elcitonin | 1.1 | 3.4 | 4.4 | 0.9 | 2.8 |
| Bredinin | 1.1 | 3.3 | 4.2 | 1.0 | 2.9 |

## Health Care (iii)

Pharmaceutical pipeline

| Development stage | Code name, form, generic name | Classifications | Indication | Region | Origin | Remarks |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Phase III | ART-123, injection, recombinant thrombomodulin alpha | Anticoagulant | Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) | Japan | In-house | Additional indication |
|  | MN-10-T, autoinjection, teriparatide acetate | Osteoporosis drug | Osteoporosis with high risk of fracture | Japan | In-house | New formulation; new dose |
| Phase II | ART-123, injection, recombinant thrombomodulin alpha | Anticoagulant | Chemotherapyinduced peripheral neuropathy (CIPN) | Japan | In-house | Additional indication |
| Pending approval (overseas) | Flivas, tablet, naftopidil | Dysuria treatment | Benign prostatic hyperplasia | China | In-house |  |
| Phase III (overseas) | ART-123, injection, recombinant thrombomodulin alpha | Anticoagulant | Severe sepsis with coagulopathy | United States, Europe, etc | In-house |  |
|  | HE-69, tablet, mizoribine | Immunosuppressant | Lupus nephritis, nephrotic syndrome | China | In-house | Additional indication |

## Critical Care

## AsahiKASEI



## Review of operations

Increased shipments of defibrillators for professional use. Firm performance of LifeVest wearable defibrillator business. Sales and operating income increase.

Financial performance of Critical Care business category
(\$ million)

|  | $\begin{aligned} & \hline \text { Oct.- } \\ & \text { Dec. } \\ & \hline \end{aligned}$ | $\begin{gathered} \text { Apr.- } \\ \text { Dec. } \\ \hline \end{gathered}$ | FY 2016 | Oct.Dec. | Apr.- <br> Dec. | FY 2017 forecast |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 318 | 930 | 1,256 | 361 | 1,047 | 1,438 |
| Gross operating income before PPA ${ }^{1}$ impact | 67 | 193 | 259 | 78 | 216 | 297 |
| Amortization/depreciation from $\mathrm{PPA}^{1}$ revaluation | (31) | (92) | (122) | (31) | (92) | (122) |
| Goodwill | (19) | (56) | (75) | (19) | (56) | (75) |
| Other intangible assets, etc. | (12) | (35) | (47) | (12) | (35) | (47) |
| Consolidated operating income | 36 | 101 | 136 | 48 | 125 | 175 |

[^12]
[^0]:    ${ }^{1}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification.

[^1]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

[^2]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

[^3]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

[^4]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

[^5]:    ${ }^{1}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category.
    FY 2016 figures are recalculated in accordance with the new classification.

[^6]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

[^7]:    ${ }^{1}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification.

[^8]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Chemicals business category. FY 2016 figures are recalculated in accordance with the new classification.

[^9]:    ${ }^{1}$ Beginning with FY 2017, the Energy Division, which was formerly included in Others, is reclassified into the Material business category. FY 2016 figures are recalculated in accordance with the new classification
    ${ }^{2}$ China, Korea, and Taiwan.

[^10]:    ${ }^{1}$ Increase (decrease) in sales prices excluding impact of foreign exchange.
    ${ }^{2}$ Impact of foreign exchange on sales prices.

[^11]:    ${ }^{1}$ As the rental management operation of Asahi Kasei Homes was transferred to Asahi Kasei Realty \& Residence, the corresponding sales previously included in order-built homes, etc., are combined with rental housing under real estate beginning with H2 2015.

[^12]:    ${ }^{1}$ Purchase price allocation.

